Hi MESuther13,

Thank you for replying,

I can assure you, I will be in this thread a lot,at least until
the FDA decision :).
I am in an growth medium term investment style for now.
but in the long run, I will try to identify long term holding too.

Back to ZGEN and Bayer,
I think ZGEN receive a fair deal.Not the best deal,but a fair deal.
My opinion is based on the help that Bayer will also provide in marketing the drug in USA local market.As we know OMRI have marketing agreement with Johnson&Johnson,an although ZGEN r-Thrombin suppose to be better performing then the OMRI one,some times drug success also depend on Marketing Power.

Not to mention Bayer ready to give upfront payment right here right now,that help ZGEN with the cash flow.Beside ZGEN should show good will,
so perhaps next time it have other potential drug coming out,lot of
company will like to deal with ZGEN.

What I really like is the way Bayer decide to pay ZGEN.It pay 30million now and 40million after approval.That show they are sure about FDA approving r-Thrombin,if they are not sure,they will pay 10million today,and 60million after approval.
What do you think?
Thank you.